Intraoperative and postoperative surgical complications after ureteroscopy, retrograde intrarenal surgery, and percutaneous nephrolithotomy: a systematic review.


Journal

Minerva urology and nephrology
ISSN: 2724-6442
Titre abrégé: Minerva Urol Nephrol
Pays: Italy
ID NLM: 101777299

Informations de publication

Date de publication:
Jun 2021
Historique:
pubmed: 24 4 2021
medline: 27 7 2021
entrez: 23 4 2021
Statut: ppublish

Résumé

Retrograde ureteroscopy (URS), intra-renal surgery (RIRS) and percutaneous nephrolithotomy (PCNL) represent routine interventions for the treatment of ureteral and renal stones, although at times associated with serious adverse events. Of note, the evidence on perioperative complications after these procedures remains sparse and controversial. Moreover, there is a lack of standardized reporting of adverse events using uniform systems. The aim of the present study was to systematically review of the available evidence on URS/RIRS and PCNL for the surgical treatment of urinary stone, assessing the incidence of intra- and postoperative events, classified according to the modified Clavien-Dindo scale. A systematic review of the literature was performed according to PRISMA recommendations and was conducted on intra- and postoperative complications, as well as on their management, following URS, RIRS and PCNL procedures, particularly focusing on major events. Overall, 26 studies (13 on URS/RIRS and 11 on PCNL) met the inclusion criteria and were evaluated. The highest intraoperative complication rate was 11.5% and 8.5% for RIRS and PCNL, respectively. Major complication rate following URS/RIRS and PCNL ranged between 0.3-31.7% and 2-17.1%, respectively. The most frequent adverse events were obstructive pyelonephritis or urinary leakage requiring the placement of a double J stent or a drainage. Among PCNLs series, life-threatening adverse events have also been reported, including bleeding requiring renal angioembolization and urothorax. Despite the inclusion of series using a standardized reporting system, the complication rate after URS/RIRS/PCNL remains extensively heterogeneous in the literature; in addition, a non-negligible proportion of studies did not characterize the adverse events nor report the actual management strategy to solve them. Future research is needed to standardize the classification and reporting of surgical complications after endourological procedures (taking into consideration the surgeon's experience and skills), aiming to improve patient counseling and potentially the strategy for their prevention.

Identifiants

pubmed: 33887891
pii: S2724-6051.21.04294-4
doi: 10.23736/S2724-6051.21.04294-4
doi:

Types de publication

Journal Article Review Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

309-332

Auteurs

Antonio A Grosso (AA)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy.

Francesco Sessa (F)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy.

Riccardo Campi (R)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy - riccardo.campi@gmail.com.
Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy.

Lorenzo Viola (L)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy.

Paolo Polverino (P)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy.

Alfonso Crisci (A)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy.

Matteo Salvi (M)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy.

Evangelos Liatsikos (E)

Department of Urology, University of Patras, Patras, Greece.

Oriol A Feu (OA)

Puigvert Foundation, Barcelona, Spain.

Fabrizio DI Maida (F)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy.

Riccardo Tellini (R)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy.

Olivier Traxer (O)

Service of Urology, Sorbonne University, Paris, France.
Tenon Hospital, Assistance-Publique Hôpitaux de Paris, Paris, France.

Andrea Cocci (A)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy.

Andrea Mari (A)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy.

Cristian Fiori (C)

Department of Urology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin, Italy.

Francesco Porpiglia (F)

Department of Urology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin, Italy.

Marco Carini (M)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy.

Agostino Tuccio (A)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy.

Andrea Minervini (A)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH